Drug development moves through four distinct phases, each answering a specific question about safety, dosing, efficacy, and long-term effects. The phase determines who can participate, what risks are involved, what compensation is offered, and what the study is trying to prove. Understanding clinical trial phases helps potential participants make informed decisions about whether and which trial to join, and helps patients waiting on new treatments understand where a drug is in the development pipeline. This guide breaks down each phase with realistic expectations on size, duration, and what participants actually experience.
Phase 1 — first testing in humans
Phase 1 is the first step where a drug or treatment moves from laboratory and animal studies into humans. The primary goal is safety and dosing, not efficacy. Researchers want to identify side effects, determine the maximum tolerated dose, and understand how the drug is absorbed, distributed, metabolized, and excreted (pharmacokinetics).
- Typical size: 20-100 participants
- Duration: 1-2 years
- Participants: often healthy volunteers, sometimes patients with the target condition (especially in oncology)
- Compensation: $1,000-7,000 for healthy volunteer studies (often involving inpatient stays)
Phase 1 is the riskiest phase because the drug has limited prior human exposure. The doses tested often start very low and escalate gradually. Studies are typically conducted at specialized clinical research units with intensive monitoring. The FDA’s drug development overview details the regulatory framework.
Phase 2 — early efficacy in target population
Phase 2 tests the drug in patients with the target condition for the first time. The goal is to establish whether the drug works at all and to refine the dosing. Researchers compare different doses, evaluate the magnitude of the effect, and continue to monitor safety in the larger and more vulnerable patient population.
- Typical size: 100-300 patients with the target condition
- Duration: 1-2 years
- Participants: patients with the specific condition being treated
- Compensation: typically $25-100 per visit for time and travel
Phase 2 is where most drug candidates fail. About 70% of drugs that enter Phase 2 don’t make it to Phase 3. The trial is large enough to detect efficacy signals but not large enough to definitively prove a drug works. Successful Phase 2 results trigger a meeting with the FDA to design the Phase 3 program.
Phase 3 — pivotal efficacy and safety
Phase 3 is the largest and most rigorous phase, designed to definitively prove the drug works and to characterize its safety in a large population. These are the trials that produce the data the FDA reviews for marketing approval.
- Typical size: 1,000-3,000 patients across multiple sites
- Duration: 2-4 years
- Participants: broader patient population with the target condition
- Compensation: similar to Phase 2, $25-100 per visit
Phase 3 trials are typically randomized, double-blind, and placebo- or active-comparator-controlled. They produce statistically powered comparisons that can support changes to medical practice. About 50% of drugs that enter Phase 3 don’t get approved — the trial may show inadequate efficacy, unacceptable safety, or commercial considerations that don’t justify continued development.
Phase 4 — post-marketing surveillance
Phase 4 happens after FDA approval and the drug is on the market. The goal is to characterize long-term safety, rare side effects that didn’t show up in earlier phases, real-world effectiveness, and use in populations not heavily studied during development.
- Typical size: thousands to hundreds of thousands of patients
- Duration: years to decades
- Participants: patients prescribed the drug as part of their normal care
- Compensation: typically not paid, since the drug is part of standard treatment
Phase 4 is sometimes a formal study (post-marketing requirement from the FDA) and sometimes observational research using insurance claims and electronic health records. Major safety findings sometimes emerge in Phase 4 that lead to label updates, new warnings, or in rare cases drug withdrawal.
How participants experience each phase
Phase 1 is the most intensive phase from a participant perspective. Healthy volunteer studies often involve multi-day inpatient stays at clinical research units, frequent blood draws, and intensive monitoring. The compensation reflects this intensity. Patient-focused Phase 1 trials (especially in oncology) involve outpatient visits with extensive monitoring.
Phase 2 and 3 trials feel more like enhanced medical visits. Participants typically come in every 2-4 weeks for the active treatment period. Visits include vital signs, lab work, questionnaires, sometimes imaging, plus the study drug administration if applicable. The schedule is structured but generally compatible with normal life.
Phase 4 trials, when conducted formally, are usually the lightest touch. Many Phase 4 studies are observational — researchers track outcomes without changing patient care. Participants in Phase 4 often don’t experience the trial as a “study” beyond signing consent forms and allowing data to be collected.
Risk levels by phase
Risk is highest in Phase 1 (least human safety data) and lowest in Phase 4 (drug already approved and widely used). Phase 1 healthy volunteer trials have produced rare but serious adverse events, including deaths, when novel drugs unexpectedly affected human biology in ways the preclinical data didn’t predict. The TGN1412 trial in 2006 and the BIA 10-2474 trial in 2016 are the most cited examples.
Phase 2 and 3 trials test drugs that have already passed earlier human safety testing, so the absolute risk is lower — though risks specific to each individual remain since the drug is still investigational. Phase 4 risk is similar to taking the approved drug as prescribed, with the added benefit of more intensive monitoring.
What phase a drug is in matters for patients
For patients with serious or rare conditions, the phase of available trials affects both access and risk. Phase 1 oncology trials, for example, often include patients with advanced disease who have exhausted standard treatments — the risk-benefit calculation differs from healthy volunteer Phase 1 trials. Phase 2 and 3 trials offer access to treatments that have already shown some safety and efficacy signals.
For specific conditions, our guides to clinical trials for breast cancer, clinical trials for Alzheimer’s, and other conditions cover what trials are typically active and what phases they tend to be in.
Frequently Asked Questions
Which phase is safest for participants?
Phase 4, since the drug is already FDA-approved and has extensive human safety data. Phase 1 has the most uncertainty about safety since drugs are first being tested in humans.
Are Phase 1 trials only for healthy people?
No. Phase 1 oncology trials typically enroll patients with advanced cancer rather than healthy volunteers. The risk-benefit calculation differs because patients have limited options. For most other conditions, Phase 1 uses healthy volunteers.
How do I know what phase a trial is in?
ClinicalTrials.gov lists the phase for every registered trial. The phase is also typically discussed in the informed consent process. Trial sponsors provide this information clearly.
Do all drugs go through all four phases?
Most prescription drugs do, though Phase 4 may be voluntary or required depending on the drug. Some drugs receive accelerated approval based on Phase 2 data with Phase 3 conducted post-approval as a confirmatory study.
How much do participants get paid?
Phase 1 healthy volunteer studies pay $1,000-7,000 for time commitment, often involving inpatient stays. Phase 2 and 3 trials typically pay $25-100 per visit. Phase 4 studies usually don’t pay because the drug is part of standard medical care. See our clinical trial compensation guide for detail.
The bottom line on clinical trial phases
The four-phase clinical trial system is designed to balance the need for evidence with patient safety. Each phase answers specific questions: Phase 1 establishes safety and dosing, Phase 2 demonstrates early efficacy, Phase 3 provides definitive evidence of effectiveness, and Phase 4 monitors real-world outcomes. Participants face different risks, time commitments, and compensation at each phase. For potential trial participants, understanding which phase a study is in is one of the most important factors in deciding whether to enroll.